Merck Novartis Merck And Novartis Financial Statements Essay

Merck Novartis Merck and Novartis Financial Statements 2012

Balance Sheet

• What components of stockholders' equity do each of the companies disclose?

Merck & Co. provides a consolidated statement of stockholders equity on their balance sheet. They disclose the number of shares, share types, retained earnings, and some historical data (Merck & Co., 2013).

Novartis provides a much more thorough and detailed report of their shareholders equity in their annual report. Not only do they report all of the same accounts as Merck, but they also provide a detailed analysis of the movements in shareholders' equity as well as many of the motivations that are responsible for changes (Novartis, 2013)

• Do the companies have preferred stock shares outstanding? If so, what special features do these shares contain?

Both companies have preferred stock. Preferred stock accounts are paid before the common stock accounts. They are given priority when there is a decision to be made about who gets paid first and how much.

• Do either of the companies report treasury...

...

Novartis received some treasury shares when it merged with Alcon as report on their financial statements (Novartis, 2013). Merck discloses their treasury holdings, however they do not discuss motivations for such on their report.
Income Statement

• What are the basic and diluted earnings per share for each company?

Merck - $3.82

Novartis - $5.25

• Have the companies reported any discontinued operations?

Yes. Merck has went through a series of cost reduction programs. As of the end of 2012 for example, Merck had achieved its projected $3.5 billion in annual net cost savings from these activities since the merger with Schering-Plough Corporation. Novartis seemed to focus more on acquisitions than cost reduction measures.

• Do the companies disclose any stock compensation plans? If so, are they reporting such plans under the fair value or intrinsic value methods? What was the value of compensation expense measured…

Sources Used in Documents:

Works Cited

Merck & Co. (2013). 2012 Annual Statement. Retrieved from Merck & Co.: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTc0MTg1fENoaWxkSUQ9LTF8VHlwZT0z&t=1

Novartis. (2013). 2012 Annual Report. Retrieved from Novartis: http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2012-en.pdf


Cite this Document:

"Merck Novartis Merck And Novartis Financial Statements" (2013, August 29) Retrieved April 19, 2024, from
https://www.paperdue.com/essay/merck-novartis-merck-and-novartis-financial-95367

"Merck Novartis Merck And Novartis Financial Statements" 29 August 2013. Web.19 April. 2024. <
https://www.paperdue.com/essay/merck-novartis-merck-and-novartis-financial-95367>

"Merck Novartis Merck And Novartis Financial Statements", 29 August 2013, Accessed.19 April. 2024,
https://www.paperdue.com/essay/merck-novartis-merck-and-novartis-financial-95367

Related Documents

Financial Accounting For Merck, the company is based in the U.S. And uses the U.S. generally accepted accounting principles (GAAP) to compile its financial statements. Novartis is based in Switzerland, and it uses international financial reporting standards (IFRS) to prepare its financial statements. It is allowed to use this as foreign firm, even though it has a cross-listing on the New York Stock Exchange, but it files a different form, the 20-C,

Financial Reports Balance Sheet Merck discloses on its balance sheet the following components of stockholders' equity: capital stock, retained earnings, additional paid-in capital, treasury stock and accrued gains/losses. Novartis reports retained earnings, additional paid-in capital and treasury stock only. Neither of these companies has any preferred shares outstanding. Both companies report treasury shares. Merck notes in its annual report that the Board "approved the purchase of up to $5.0 billion of Merck's common

Procter vs. J&J Procter & Gamble and Johnson & Johnson are very similar a lot of tangible ways. The major similarities include the fact that they are both sellers of common and widely used consumable products, they are both mainstays of the corporation scene in the United States and neither one of them has ever had any major systemic issues since their founding. Even so, there are some notable and real

Direct to Consumer Advertising HISTORY OF DRUG ADVERTISING THE DTC ADVERTISING PHENOMENON CREATING DEMAND DECEPTIVE ADVERTISING - A WOLF IN SHEEP'S CLOTHING CAUSE OF DEATH PROFIT UTILIZATION, PRICING, AND DEMOGRAPHICS LEGISLATION, POLITICS AND PATENTS LEGISLATIVE INITIATIVES REGARDING DTC RECALLED and/or DEADLY DRUGS In order to provide the most efficient method of evaluation, the study will utilize existing stores of qualitative and quantitative data from reliable sources, such as U.S. Government statistical references, University studies, and the studies and publications of non-profit

JOHNSON & JOHNSON The Fundamental Analysis of Johnson & Johnson Inc. (J& J, 2005) Economic and Market Analysis Globalization Industry Analysis Company Analysis Brief History of the Company Analysis of Capital Asset Pricing Model Intrinsic Value Valuation Measures Trading Information Competitors Awards & Recognition Our modern business world consists of an extremely competitive global economy where manufactures search for opportunities to strategically reduce costs and increase market share and profitability. Historically, the most often chosen solution for holding down costs was to systematically reduce

309). The abbreviated approval process authorized by Hatch-Waxman lets generic drug manufacturers use the same clinical data that the original manufacturer used to obtain FDA approval, thereby avoiding these expenses. In this regard, Greene emphasizes that, "Whereas the pioneer drug manufacturer must incur great expense and undergo rigorous scrutiny when it files an new drug application (NDA) to secure FDA approval, a generic manufacturer may file an Abbreviated New Drug